Logo image of ALPN

ALPINE IMMUNE SCIENCES INC (ALPN) Stock Fundamental Analysis

USA - NASDAQ:ALPN - US02083G1004 - Common Stock

64.97 USD
+0.01 (+0.02%)
Last: 5/17/2024, 8:00:01 PM
64.99 USD
+0.02 (+0.03%)
After Hours: 5/17/2024, 8:00:01 PM
Fundamental Rating

4

ALPN gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 541 industry peers in the Biotechnology industry. While ALPN has a great health rating, there are worries on its profitability. ALPN is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

ALPN had negative earnings in the past year.
In the past year ALPN has reported a negative cash flow from operations.
In the past 5 years ALPN always reported negative net income.
ALPN had negative operating cash flow in 4 of the past 5 years.
ALPN Yearly Net Income VS EBIT VS OCF VS FCFALPN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20M -20M -40M -60M

1.2 Ratios

With an excellent Return On Assets value of -9.86%, ALPN belongs to the best of the industry, outperforming 87.99% of the companies in the same industry.
Looking at the Return On Equity, with a value of -11.07%, ALPN belongs to the top of the industry, outperforming 90.05% of the companies in the same industry.
Industry RankSector Rank
ROA -9.86%
ROE -11.07%
ROIC N/A
ROA(3y)-16.1%
ROA(5y)-29.01%
ROE(3y)-27.88%
ROE(5y)-54.08%
ROIC(3y)N/A
ROIC(5y)N/A
ALPN Yearly ROA, ROE, ROICALPN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 -50 -100

1.3 Margins

ALPN does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ALPN Yearly Profit, Operating, Gross MarginsALPN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 -1K -2K -3K -4K -5K

More info and screens

8

2. Health

2.1 Basic Checks

ALPN does not have a ROIC to compare to the WACC, probably because it is not profitable.
ALPN has more shares outstanding than it did 1 year ago.
ALPN has more shares outstanding than it did 5 years ago.
ALPN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ALPN Yearly Shares OutstandingALPN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M
ALPN Yearly Total Debt VS Total AssetsALPN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M

2.2 Solvency

ALPN has an Altman-Z score of 64.87. This indicates that ALPN is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of ALPN (64.87) is better than 98.46% of its industry peers.
ALPN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 64.87
ROIC/WACCN/A
WACC9.11%
ALPN Yearly LT Debt VS Equity VS FCFALPN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 100M 200M 300M

2.3 Liquidity

A Current Ratio of 9.56 indicates that ALPN has no problem at all paying its short term obligations.
ALPN's Current ratio of 9.56 is fine compared to the rest of the industry. ALPN outperforms 74.96% of its industry peers.
A Quick Ratio of 9.56 indicates that ALPN has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 9.56, ALPN is in the better half of the industry, outperforming 75.13% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 9.56
Quick Ratio 9.56
ALPN Yearly Current Assets VS Current LiabilitesALPN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M

More info and screens

6

3. Growth

3.1 Past

ALPN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 60.82%, which is quite impressive.
The Revenue has grown by 118.80% in the past year. This is a very strong growth!
The Revenue has been growing by 141.96% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)60.82%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)118.8%
Revenue growth 3Y84.73%
Revenue growth 5Y141.96%
Sales Q2Q%-25.09%

3.2 Future

ALPN is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -13.31% yearly.
The Revenue is expected to grow by 33.81% on average over the next years. This is a very strong growth
EPS Next Y-157.63%
EPS Next 2Y-70.39%
EPS Next 3Y-54.78%
EPS Next 5Y-13.31%
Revenue Next Year-56.25%
Revenue Next 2Y-32.39%
Revenue Next 3Y-34.72%
Revenue Next 5Y33.81%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
ALPN Yearly Revenue VS EstimatesALPN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 500M 1B 1.5B
ALPN Yearly EPS VS EstimatesALPN Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 5 -5 10 15

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ALPN. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ALPN. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ALPN Price Earnings VS Forward Price EarningsALPN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 -50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ALPN Per share dataALPN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4

4.3 Compensation for Growth

ALPN's earnings are expected to decrease with -54.78% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-70.39%
EPS Next 3Y-54.78%

More info and screens

0

5. Dividend

5.1 Amount

ALPN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ALPINE IMMUNE SCIENCES INC

NASDAQ:ALPN (5/17/2024, 8:00:01 PM)

After market: 64.99 +0.02 (+0.03%)

64.97

+0.01 (+0.02%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-09 2024-05-09/amc
Earnings (Next)08-12 2024-08-12/amc
Inst Owners5.3%
Inst Owner Change0%
Ins Owners18.43%
Ins Owner Change0%
Market Cap4.46B
Analysts76
Price Target62.73 (-3.45%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)84.33%
Min EPS beat(2)33.62%
Max EPS beat(2)135.04%
EPS beat(4)4
Avg EPS beat(4)56.9%
Min EPS beat(4)29.29%
Max EPS beat(4)135.04%
EPS beat(8)5
Avg EPS beat(8)-18.51%
EPS beat(12)5
Avg EPS beat(12)-928.68%
EPS beat(16)6
Avg EPS beat(16)-710.5%
Revenue beat(2)2
Avg Revenue beat(2)164.17%
Min Revenue beat(2)96.1%
Max Revenue beat(2)232.25%
Revenue beat(4)3
Avg Revenue beat(4)89.84%
Min Revenue beat(4)-4.81%
Max Revenue beat(4)232.25%
Revenue beat(8)4
Avg Revenue beat(8)23.35%
Revenue beat(12)5
Avg Revenue beat(12)4.08%
Revenue beat(16)6
Avg Revenue beat(16)-4.07%
PT rev (1m)-0.81%
PT rev (3m)83.19%
EPS NQ rev (1m)3.87%
EPS NQ rev (3m)-9.12%
EPS NY rev (1m)0%
EPS NY rev (3m)-26.02%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-35.09%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-48.45%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 78.86
P/FCF N/A
P/OCF N/A
P/B 13.4
P/tB 13.4
EV/EBITDA N/A
EPS(TTM)-0.67
EYN/A
EPS(NY)-1.95
Fwd EYN/A
FCF(TTM)-1.18
FCFYN/A
OCF(TTM)-1.17
OCFYN/A
SpS0.82
BVpS4.85
TBVpS4.85
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -9.86%
ROE -11.07%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-16.1%
ROA(5y)-29.01%
ROE(3y)-27.88%
ROE(5y)-54.08%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.15
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 71.36%
Cap/Sales 0.74%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 9.56
Quick Ratio 9.56
Altman-Z 64.87
F-Score5
WACC9.11%
ROIC/WACCN/A
Cap/Depr(3y)57.41%
Cap/Depr(5y)96.93%
Cap/Sales(3y)0.9%
Cap/Sales(5y)11.68%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)60.82%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y-157.63%
EPS Next 2Y-70.39%
EPS Next 3Y-54.78%
EPS Next 5Y-13.31%
Revenue 1Y (TTM)118.8%
Revenue growth 3Y84.73%
Revenue growth 5Y141.96%
Sales Q2Q%-25.09%
Revenue Next Year-56.25%
Revenue Next 2Y-32.39%
Revenue Next 3Y-34.72%
Revenue Next 5Y33.81%
EBIT growth 1Y22.51%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-66.67%
EBIT Next 3Y-35.27%
EBIT Next 5Y-25.05%
FCF growth 1Y-1436.11%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-1405.54%
OCF growth 3YN/A
OCF growth 5YN/A